CN112674932A

CN112674932A - Light biological regulation therapeutic apparatus for treating open-angle glaucoma and using method

Info

Publication number: CN112674932A
Application number: CN202110032582.1A
Authority: CN
Inventors: 钟华; 陈琴; 朱勤; 陶奕瑾; 寸青; 杨文艳
Original assignee: First Affiliated Hospital of Kunming Medical University
Current assignee: First Affiliated Hospital of Kunming Medical University
Priority date: 2021-01-12
Filing date: 2021-01-12
Publication date: 2021-04-20

Abstract

The invention discloses a photobiological adjustment therapeutic apparatus for treating open-angle glaucoma and a method of using the same. By setting the relative light-emitting viewpoint brightness of left and right eyeglasses to near-infrared light with a wavelength of 600-800 nm, the eye cells of glaucoma patients are activated Internal photoreceptors, which promote the conversion of light energy into metabolic energy, reduce intraocular pressure in patients with glaucoma, and provide a greater possibility for patients to recover their vision. On the one hand, by irradiating the ciliary body of the eye, it reduces the production of aqueous humor, promotes the return of aqueous humor, and reduces intraocular pressure. Cells require high-energy mitochondrial ATP to meet tissue demands and are very sensitive to glucose depletion or energy deficiency, oxidative stress, and mitochondrial dysfunction. Near-infrared light can promote mitochondrial damage repair and improve mitochondrial function, which has important application value in the treatment of optic nerve injury.

Description

Light biological regulation therapeutic apparatus for treating open-angle glaucoma and using method

Technical Field

The invention relates to treatment equipment for primary open-angle glaucoma, in particular to a photobiological regulation treatment instrument for treating open-angle glaucoma and a using method thereof.

Background

Primary Open Angle Glaucoma (POAG) is a chronic degenerative disease often accompanied by elevated intraocular pressure, characteristic depressions in the optic disc, and typical visual field defects. Irreversible functional and anatomical changes are considered as direct consequences of different risk factors, in particular increased intraocular pressure. In the 40 year old population, the prevalence of POAG is 2%. It is estimated that over 7000 million people worldwide are affected. Current treatment regimens for POAG include topical application and surgery, with the goal of lowering intraocular pressure to a presumed personal target value. While these therapies may slow the progression of glaucoma, they do not prevent irreversible vision loss. Therefore, POAG is still the third most common cause of blindness in the world, placing a significant burden on healthcare and social systems. Over the past decade, the availability of glaucoma medication and the use of laser trabeculoplasty have increased, with a concomitant decrease in invasive incision surgery; in addition, some novel minimally invasive glaucoma surgeries have emerged, filling the gap between conservative medical management and large-incision surgery.

1. Endoscopic laser ciliary photocoagulation (ECP): the ECP observes the ciliary process under the direct vision of the endoscope, the laser probe is extended into the eye through the tiny incision, and the treatment is implemented by precisely controlling the laser energy aiming at the ciliary body, so theoretically, the ECP can enable the treatment operation to be more precise, and the intraocular pressure is reduced by reducing the secretion of aqueous humor. ECP has less damage to ciliary body, can avoid the damage of adjacent tissues and eyeball atrophy, lightens postoperative inflammatory reaction and reduces the risk of low intraocular pressure. Compared to other techniques of MIGS, ECP can be used for the clinical treatment of early-to-middle-stage, advanced and refractory glaucoma, but after ECP surgery treatment, part of the ciliary body can restore the function of aqueous humor secretion, the intraocular pressure is increased again, and the patient may need to re-use anti-glaucoma drugs or perform ECP surgery again.

2. High intensity focused ultrasound ciliary body plasty (UCP) UCP is suitable for both open angle glaucoma and closed angle glaucoma, can be applied in early stage or late stage of disease, and is especially suitable for refractory glaucoma which can not be controlled by medicine or operation. Meanwhile, the operation can be combined with other operations and can be repeatedly applied. The post-operative part of the patients experienced blurred vision within 1-2 weeks but recovered quickly. The technique has the advantages of wide adaptation, high accuracy, safety, no incision, simple operation, short operation time, rapid recovery, no risk of intraocular infection, and light postoperative pain response. Such as ocular hypertension after the first treatment, or gradual reduction of the therapeutic effect over time, and repeated ultrasound treatment if necessary.

Compared with the traditional filterable surgery, the MIGS is simpler and more efficient, the medication burden of patients is reduced, the complications are relatively reduced, the risk of complex surgery is avoided, and the future development direction of glaucoma surgery is formed. As the clinical application of the new technology in China is in a primary stage, large samples need to be made in the future, random contrast tests and the like are used for clinical exploration, the success or failure factors of each operation are explored, and meanwhile, all glaucoma treatment operations in the past can only reduce intraocular pressure and relieve optic nerve atrophy speed, but cannot protect optic nerves and even cannot reverse optic nerve damage.

Disclosure of Invention

The present invention addresses the above-described deficiencies of the prior art by providing a photobioregulatory therapeutic device for the treatment of open angle glaucoma and a method of use.

The invention is realized by the following technical scheme: the optical biological regulation therapeutic apparatus for treating open-angle glaucoma activates the optical receptors in the eye cells of the glaucoma patient by setting the relative luminous viewpoint brightness of the left and right eye sight glasses of the therapeutic apparatus to be near infrared light of 600-.

Further, the luminous viewpoint is near infrared light of 630nm ± 10 nm.

The invention has the advantages that:

the photobiologic therapy is used for treating open-angle glaucoma, and on one hand, can reduce the generation of aqueous humor, promote the backflow of the aqueous humor and reduce the intraocular pressure by irradiating the ciliary body part of an eyeball. The mechanism is as follows: low intensity laser radiation can reduce aqueous fluid production and enhance aqueous fluid drainage by directly and simultaneously stimulating the sympathetic and parasympathetic nervous systems. Adrenergic stimulation reduces water production, while cholinergic stimulation may improve water excretion through Schlemm's canal. Thus, photomodulatory therapies can both lower IOP and stimulate the regenerative process, thereby reducing glaucoma damage. On the other hand, low-dose red light irradiation may reduce glaucoma optic nerve damage and promote repair of damaged optic nerve, and the mechanism is as follows: the red light warming effect allows relaxation of retinal and vascular smooth muscle cells, and subsequent vasodilatation improves the microcirculation of retinal and choroidal tissues, thereby reducing the characteristics of ischemia and hypoxia. In addition, neurons of the optic nerve require high-energy mitochondrial ATP to meet the needs of the tissue and are very sensitive to glucose consumption or energy deficiency, oxidative stress and mitochondrial dysfunction. The near infrared light can promote the repair of mitochondrial damage and improve the mitochondrial function, and has important application value in the treatment of optic nerve damage.

Drawings

FIG. 1 is a schematic view of the biological regulating apparatus of the present invention.

In the figure: 1-luminous viewpoint, 2-left and right sight glasses.

Detailed Description

The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.

The near-infrared light is the near-infrared light with the spectral range of 600-1100nm generated by the light-emitting diode. The light receptor in the cell is sensitive to the wave band, particularly 600-700nm is an optical window for in-vivo treatment, the penetrating power is strong but not enough to cause tissue cell damage, the light receptor in the cell is activated, a signal channel is triggered, the cell metabolism is influenced, and the light energy is converted into the metabolic energy. Near infrared light can significantly increase the activity of cytochrome oxidase and superoxide dismutase, suggesting a beneficial role in inducing metabolism and antioxidant effects. In addition, near infrared light may also promote cerebral blood flow and cognitive function in humans without adverse effects. We have found that low levels of laser irradiation help to lower intraocular pressure in glaucoma patients.

As shown in figure 1, the invention provides a photobiological regulation therapeutic instrument for treating primary open-angle glaucoma, which comprises a luminous viewpoint 1 and left and right eye glasses 2, wherein the wavelength range of the left and right eye glasses is 600-800 nm. The required light is low dose red light generated by a continuous light emitting diode, and the wavelength range is 600-800 nm. Each patient receives treatment once or twice a day until intraocular pressure is not further influenced and visual field is stable, besides the optical biological regulation therapeutic apparatus provided by the invention, various optical biological regulation therapeutic apparatuses on the market can be selected, for example, an amblyopia comprehensive therapeutic apparatus produced by Zuoguan medical apparatus Limited in Suzhou industrial park, and instruments which only need to regulate red light to the wavelength of 600-800nm belong to the design spirit of the invention.

The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.

Claims

1. The optical biological regulation therapeutic apparatus for treating open-angle glaucoma is characterized in that a near infrared light with the relative luminous viewpoint brightness of the left and right eye mirrors of the therapeutic apparatus being 600 minus 800nm wavelength is set, the emission duration is 160 minus 190 seconds, an optical receptor in an eye cell of a glaucoma patient is activated, optical energy is promoted to be converted into metabolic energy, the intraocular pressure of the glaucoma patient is reduced, and greater possibility is provided for the visual recovery of the patient.

2. The photomodulatory therapeutic apparatus for treating open angle glaucoma according to claim 1, wherein the light emission viewpoint is near infrared light of 630nm ± 10 nm.

3. Method of use of a photo-bioregulatory therapeutic apparatus for the treatment of open angle glaucoma, characterized in that the patient is treated with both eyes at the luminous eye point for 90 seconds each time, each patient receiving one or two treatments per day until the intraocular pressure is no longer further affected and the visual field is stable.